2.3M
Downloads
130
Episodes
Intended for the medical professional who enjoys learning for the sake of it. Dr. Porat is a practicing Colorado Hospitalist and Board Certified in Internal Medicine.
Episodes
Thursday Jan 27, 2022
Thursday Jan 27, 2022
The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF).
Now let us dig a bit more into those headlines.
No comments yet. Be the first to say something!